GlassScriptPhysician profile
Ryan R Busch
NPI 1831590504
$501.68
in general payments reported to CMS, 2019-2025
18 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $316 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $61.10 | 2024-2025 | Rybelsus, Ozempic |
| Collegium Pharmaceutical, INC. | $59.66 | 2024 | Xtampza, Belbuca |
| Cranial Technologies, INC | $35.39 | 2024-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $33.00 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $31.81 | 2025 | |
| Glaxosmithkline, LLC. | $30.84 | 2024-2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $30.48 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $28.65 | 2024 | |
| Edwards Lifesciences Corporation | $27.95 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Supernus Pharmaceuticals, INC. | $27.54 | 2024 | Qelbree |
| Corcept Therapeutics | $21.63 | 2024 | Korlym |
| Viatris Specialty LLC | $20.41 | 2025 | Yupelri |
| Abbvie INC. | $17.48 | 2025 | |
| Pfizer INC. | $16.38 | 2024 | |
| Aimmune Therapeutics, INC. | $16.09 | 2025 | Zenpep |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.80 | 2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.02 | 2024 | Caplyta |
| Lilly USA, LLC | $13.45 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.